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Abstract
The regulation of chromatin structure and gene expression depends substantially on a 
dynamic and intricate layer of biological and chemical information that constitutes the 
epigenome. This epigenetic layer of information holds fundamental clues to the molecu-
lar mechanisms, not yet fully understood, by which a genotype can influence and con-
figure a specific phenotype. A profound understanding of the molecular underpinnings 
of epigenetic processes is, thus, essential to wield deliberate spatiotemporal control of 
gene activation and repression. However, only recently has the technology required to 
adequately probe the functional significance of specific epigenetic mechanisms become 
available. This chapter provides an overview of modern epigenome editing systems, 
including zinc finger proteins, TAL effectors, and CRISPR–Cas systems. It highlights the 
use of biotechnological tools to investigate the role of DNA and histone post-translational 
modifications as well as regulatory RNAs to manipulate specific patterns of gene expres-
sion. This chapter further discusses the technological limitations that have limited our 
ability to elucidate epigenetic mechanisms in local and genome-wide contexts.
Keywords: epigenome editing, epigenetic manipulation, CRISPR, CRISPR–dCas9, 
ZFNs, TALENs, epigenome engineering, targeted gene activation and repression, 
epigenetics
1. Introduction
Elucidating the underlying basis for the molecular links that bridge the gap between geno-
type and phenotype has propelled research and scientific discovery for decades. More than 
three-quarters of a century have passed since Conrad Waddington introduced the concept 
of “epigenetics.” The term signaled an attempt to describe the causal links by which genes 
give rise to specific phenotypes in the context of developmental changes that drive cellular 
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differentiation [1]. Waddington’s “epigenetic landscapes” [2] laid a foundation for exploring 
phenotypic plasticity as a phenomenon that is not entirely dependent on genetic mechanisms, 
but one which can also be shaped by environmental cues that concomitantly orchestrate the 
process of cell differentiation from an initial totipotent state [3].
The scope of epigenetics as a scientific discipline, much like its definition, has expanded with the 
passage of time. Today, the field broadly refers to the study of fundamental processes related to 
mitotic and meiotic stable and heritable changes that emerge without alteration of DNA sequences 
[3–5]. Stable changes encompass durable alterations in gene expression patterns, which may be 
neither permanent nor heritable. In contrast, heritable changes in gene expression may constitute 
persistent alterations that are carried onto the progeny of cells or individual organisms [6].
In the last two decades, the emerging field of epigenetics has revealed crucial information 
about the regulation of chromatin states in the eukaryotic nucleus. Heterochromatic DNA is 
organized into compact, higher order, chromatin fibers. By contrast, euchromatic DNA com-
prises lightly packed chromatin that represents an active and accessible part of the genome. 
Both states feature an array of nucleosomes, the basic subunits of chromatin, consisting of 
approximately 145–147 base pairs of DNA wrapped around a core histone octamer [7]. Each 
histone octamer carries two copies of all of the core histone proteins—H2A, H2B, H3, H4—
assembled into nucleosomes, which are subsequently stabilized into high-order chromatin 
structures by the presence of the linker histone H1 and linker DNA [7].
The organization and regulation of chromatin at the epigenetic level depend on dynamic 
and diverse combinations of covalent chemical modifications that occur on histone proteins—
known as histone post-translational modifications (PTMs)—and DNA bases, as well as the 
expression of regulatory noncoding RNA (ncRNA) molecules [3]. Together, these epigenetic 
signals and ncRNAs constitute a layer of information that controls the spatiotemporal regula-
tion of gene expression patterns by remodeling the structure of chromatin and modulating its 
bio-physicochemical properties.
The scientific community has made great strides in elucidating functional roles for epigenetic 
processes in recent years. Progress has come at the hand of biotechnologies aimed at manipu-
lating endogenous, site-specific epigenetic targets. The technologies rely on the use of catalyti-
cally active or scaffolding epigenetic effectors fused to programmable DNA-binding proteins 
that target specific genetic loci. This chapter focuses on the three most important platforms for 
modern targeted epigenome editing: zinc finger proteins, transcription activator-like effec-
tors (TALEs), and clustered, regularly interspaced, short palindromic repeats (CRISPR), and 
CRISPR-associated sequences (Cas) (CRISPR–Cas) systems.
Notwithstanding the progress made in recent years, much remains to be learned about 
epigenetic mechanisms in development, cellular programming, disease, and personalized 
medicine. Epigenome editing technologies are poised to make significant contributions to the 
field of epigenetics. This chapter provides an overview of each epigenome editing system, 
highlights their use for manipulating specific patterns of gene expression, and discusses the 
technological limitations that have thus far limited our ability to interrogate the mechanisms 
of epigenetic regulation in local and genome-wide contexts.
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2. Programmable epigenome editing systems
Regulating endogenous levels of gene expression by targeting specific epigenetic modifications 
is a relatively nascent field. Basic scientific research in the last few decades has provided insights 
that facilitated the development of technologies aimed at interrogating epigenetic processes. At 
their core, epigenome editing tools are based on the concept of fusing programmable DNA-
binding proteins that target specific genetic loci, with catalytically active or scaffolding effector 
domains that exert some influence on epigenetic processes. The three most important molecular 
tools that have been developed for targeted epigenome editing are zinc finger proteins, TALEs, 
and CRISPR–Cas systems. All have been repurposed into epigenome editing platforms designed 
to manipulate gene expression patterns in particular contexts. An overview of each system is pro-
vided below. However, it should be noted that other, less common, tools have also been devel-
oped to probe epigenetic mechanisms and modulate gene expression in a sequence-dependent 
manner including synthetic polyamides [8] and triple helix-forming oligonucleotides (TFOs) [9].
2.1. Zinc finger-based systems
Zinc finger proteins are among the most characterized systems used for the manipulation 
of targeted, sequence-specific nucleic acids. Their discovery arose from research of tran-
scriptional mechanisms in Xenopus laevis oocytes dating back to over three decades ago. At 
the time, scientists realized that a unique set of proteins, containing repetitive zinc-binding 
domains of roughly 30 amino acid residues, was required for transcription factor-mediated 
gene regulation [10]. These finger-like peptide arrangements rely on interactions between 
conserved pairs of cysteine and histidine residues that are anchored by a centered and tet-
rahedrally coordinated zinc ion (Figure 1). From a structural standpoint, each zinc finger 
Figure 1. Crystal structure of two zinc finger proteins in complex with DNA. (A) Recognition of target DNA (blue) by 
two distinct zinc finger proteins (orange and green). A tetrahedrally coordinated zinc ion (red) stabilizes each zinc finger 
motif. (B) Orthogonal view of zinc finger-mediated DNA recognition. [PDB 3DFX].
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comprises an antiparallel β sheet and α helix, which are stabilized by the zinc ion and a set of 
hydrophobic residues [11]. The α helix of each zinc finger binds directly to the major groove 
of B-DNA. Residues from the NH
2
-terminal region of the helix mediate recognition of a three 
base-pair target site [11]. Thus, side chain residues in the α helix that can be engineered to 
recognize diverse nucleic acid base-pair triplets drive the double-stranded DNA sequence 
specificity of each zinc finger.
The intrinsic modularity of DNA recognition by zinc finger proteins led to the swift develop-
ment of a range of biotechnological applications. For example, manipulation of gene expres-
sion via site-specific, DNA-binding zinc finger proteins was first established by targeting a 9 
base-pair region of a BCR-ABL fusion oncogene [12]. Using a three-zinc finger peptide, scien-
tists demonstrated that transcriptional repression of a leukemic oncogene in a chromosomal 
DNA context was possible [12].
Similarly, the development of zinc finger nucleases (ZFNs) marked an important milestone 
for modern genome editing biotechnologies. ZFNs are engineered chimeric fusions composed 
of a set of tandem zinc finger DNA-binding proteins and a nuclease domain—such as the 
catalytic domain of the restriction endonuclease FokI—that cleaves DNA [13]. Synthetic zinc 
finger-FokI fusions coupled the DNA sequence specificity of zinc finger proteins with the non-
specific cleavage activity of FokI to trigger double-stranded breaks at desired genomic loci. 
Importantly, repurposing zinc finger proteins into ZFNs facilitated the path for epigenome 
editing biotechnologies aimed at controlling transcriptional activation and repression.
Zinc finger-related epigenome editing tools are based on the concept of fusing program-
mable, DNA binding, zinc finger proteins designed to target diverse sequences [14, 15] with 
catalytically active or scaffolding effector domains. The chimeric proteins are designed to alter 
gene expression patterns and act as artificial transcription factors (ATFs) [15]. Pioneer studies 
on transcriptional repression by directing DNA cytosine methylation [16] and local histone 
H3K9 methylation [17] deposition at specific promoter sequences established the feasibility of 
the approach in the late 1990s and early 2000s. The use of zinc finger-based epigenome edit-
ing tools has contributed valuable insights into epigenetic mechanisms, as will be discussed 
in the next section. However, the high cost and technical expertise required to engineer and 
validate context-dependent specificity in zinc finger proteins [18, 19] has greatly limited their 
widespread adoption.
2.2. TALE-based systems
Transcription activator-like effectors (TALEs) are proteins of bacterial origin. They were first 
reported in the literature in 2007, after two independent research groups discovered that cer-
tain bacterial proteins can bind specific promoter sequences in eukaryotic cells [20, 21]. Upon 
binding to DNA, the pathogenic effector proteins induce the expression of genes that promote 
the spread of bacterial infection in host cells. TALEs are secreted by gram-negative bacteria of 
the Xanthomonas genus and injected into eukaryotic cells via the type III secretion system [22]. 
Once inside the eukaryotic cell, they translocate directly to the nucleus where they act as tran-
scription factors to regulate the expression of genes that support bacterial infection [20, 21].
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The molecular basis for DNA recognition of each TALE comes from a central tandem amino 
acid repeat domain of approximately 33–35 residues in length [23, 24]. This tandem repeat is 
flanked by an N-terminal region required for type III secretion and a C-terminal region involved 
in nuclear localization and transcriptional activation. Each repeat folds into two left-handed α 
helices linked by a short loop that contains two hypervariable residues, known as the repeat 
variable diresidues (RVDs). The RVDs occupy positions 12 and 13 of each repeat, where the 
12th residue stabilizes the RVD loop by mediating contacts with the protein backbone, while 
the 13th residue interacts directly with a specific nucleotide nitrogenous base (Figure 2). Thus, 
the DNA specificity of TALEs is modular and encoded in the tandem repeat sequence [25, 26].
Unlike zinc fingers, which require triplet sequence recognition sites, TALEs are able to target a 
single nucleotide at a time through its RVDs. This characteristic makes TALEs simpler to engi-
neer and has enabled the rational design of artificial TALEs for biotechnological applications 
[26]. Indeed, borrowing from its ZFN predecessors, TALE proteins fused to the FokI nuclease 
domain gave rise to TALE nucleases (TALENs), which have been utilized for genome editing 
applications [27].
Similarly, fusions of TALEs to epigenetic effectors have been repurposed for epigenome editing 
to manipulate gene expression. For example, TALE fusions to activation domains have shown 
the ability to target specific genomic loci and induce robust transcriptional activation [28]. 
Inactivation of enhancer regulatory elements has also been demonstrated using TALE fusions to 
chromatin effectors targeting specific histone modifications [29], thereby establishing a platform 
to interrogate the function of specific regulatory elements in diverse chromatin landscapes.
Figure 2. Structure of a TAL effector bound to its target DNA. (A) The TALE tandem amino acid repeats (multi-colored 
helices) associate into a right-handed superhelix that wraps around the major groove of the target DNA (blue). (B) 
Orthogonal view of target DNA recognition by a TALE [PDB 3UGM].
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Despite the advantages of possessing modular properties compared to zinc finger proteins 
and the improvements made in design and assembly of custom TALE-based systems [30, 
31], significant technological shortcomings remain to be addressed. The highly repetitive 
sequences associated with TALE tandem repeats make them susceptible to rearrangements 
when expressed in target cells due to recombination events that trigger deletions [32]. 
Moreover, the sheer size of TALE repeats creates obstacles to cellular delivery using some 
standard viral vectors—e.g., lentiviruses [32]. Such limitations have precluded wider adapt-
ability of TALE-based tools for epigenome editing.
2.3. CRISPR–Cas–based systems
Clustered, regularly interspaced, short palindromic repeats (CRISPR) and CRISPR-associated 
sequences (Cas) constitute bacterial and archaeal endogenous adaptive immunity systems. 
They were first reported over three decades ago upon publication of findings of a cryptic clus-
ter of unknown function in the bacterium Escherichia coli [33]. Advances in  bioinformatics—
alongside greater access to bacterial genomes in public databases around the turn of the 
century—led to the realization that such clusters exist in a wide range of bacteria and archaea 
[34]. Interest about the functional significance of the clusters in the scientific community grew 
steadily, which eventually led researchers to empirical evidence that CRISPR–Cas systems 
provide adaptive immunity against attack by viruses and plasmids [35] Figure 3.
Figure 3. Structural representation of CRISPR–Cas9 in complex with target double-stranded DNA and sgRNA. (A) 
Crystal structure of the CRISPR–Cas9 nuclease (gray) bound to a sgRNA (orange) and double-stranded target DNA 
(blue) primed for cleavage. Mutation of two Cas9 residues within the RuvC and HNH nuclease domains—D10A and 
H840A (green spheres)—abolishes the catalytic activity of the enzyme and transforms it into dCas9, which is able to 
bind its target sequence without triggering DNA cleavage. (B) Schematic cartoon representation of the CRISPR–Cas9–
sgRNA–DNA complex (colors as shown in A). [PDB 5F9R].
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CRISPR–Cas systems are currently classified into class 1 and class 2 groups, which are further 
divided into six different types and multiple subtypes [36]. Adaptive immunity to foreign nucleic 
acids is encoded in CRISPR arrays, which contain DNA sequences derived from the integration 
of invasive DNA as a new CRISPR spacer. CRISPR arrays are transcribed into precursor CRISPR 
RNAs (pre-crRNAs) and subsequently processed into mature CRISPR RNAs (crRNAs). After 
processing takes place, crRNAs mediate interference by acting as guides that recruit a variety of 
Cas effector proteins to complementary nucleic acids from invasive genetic elements [36]. Unlike 
zinc finger- and TALE-based systems, which rely on protein-DNA interactions to target specific 
genetic loci, CRISPR–Cas systems are DNA-encoded and RNA-guided. Thus, CRISPR–Cas sys-
tems harness nature’s principles of Watson-Crick base pairing of nucleic acids to identify the 
target genetic loci. This property confers significant advantages to CRISPR–Cas systems because 
they bypass the need for complex protein engineering to mediate DNA recognition.
The type II CRISPR–Cas9 system is the most characterized CRISPR–Cas system to date. This 
complex requires dual RNA molecules—a crRNA and a trans-activating crRNA (tracrRNA)—
that hybridize together and direct Cas9, a DNA endonuclease, to a target DNA sequence. 
Upon target recognition, Cas9 triggers double-stranded breaks a few nucleotides away from 
a protospacer adjacent motif (PAM) site [37]. The RNA-guided Cas9 endonuclease cleaves 
double-stranded DNA via conserved RuvC and HNH nuclease domains, which form a com-
pact catalytic core [38].
In recent years, the CRISPR–Cas9 system has been repurposed into an efficient genome edit-
ing tool by engineering a chimeric single guide RNA (sgRNA) that fuses the crRNA and 
tracrRNA into a programmable RNA molecule capable of sequence-specific DNA targeting 
[37]. Genome editing biotechnological applications take advantage of Cas9-induced double-
stranded DNA breaks to mediate DNA repair via one of two pathways: nonhomologous 
end joining (NHEJ), which introduces insertion or deletion mutations, or homology-directed 
repair (HDR), which introduces specific mutations or DNA sequences by recombination with 
a donor template. Importantly, adapting the CRISPR–Cas9 system for gene editing has also 
paved the path for repurposing the system for epigenome editing applications.
CRISPR-Cas9–mediated epigenome editing is based on the use of an engineered Cas9 protein, 
which has been purposefully stripped of its catalytic activity into a nuclease-null or “dead” 
Cas9 (dCas9). Mutating two residues—D10A and H840A—located in the RuvC and HNH 
nuclease domains is necessary and sufficient to deactivate the nuclease activity of the enzyme 
[38]. The mutations allow CRISPR–Cas9 to target specific DNA sequences and bind to them 
without cleaving DNA. Epigenetic effector proteins can then be fused to dCas9 to trigger 
desired local epigenetic changes, in much the same way mentioned earlier using zinc finger 
and TALE fusions to epigenetic effectors.
CRISPR–dCas9 has recently been used to demonstrate the feasibility of targeting specific epi-
genetic modifications to trigger transcriptional activation or repression. For instance, tether-
ing dCas9 to an epigenetic effector that acetylates histone tail residues led to transcriptional 
activation in one study [39], and a dCas9 fusion to a repression domain showed the CRISPR–
dCas9 system’s ability to recruit a heterochromatin-forming complex to silence gene expres-
sion [40]. The next section discusses these and other epigenome editing studies in more detail.
Epigenome Editing
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3. Epigenome editing to regulate gene expression
Manipulation of endogenous gene expression at target loci has thus far been achieved by cou-
pling DNA-binding proteins with (1) transcriptional activators and repressors, which modu-
late gene expression by acting as site-specific ATFs, or (2) epigenetic effectors, which catalyze 
the deposition or removal of specific epigenetic modifications at target loci. In addition, the 
CRISPR–dCas9 system has recently enabled engineering of modular sgRNA molecules that 
carry RNA aptamers as scaffolding platforms to recruit molecules for site-specific regulation.
3.1. Transcriptional activation
Transcriptional activator effector domains were first used to upregulate levels of gene expres-
sion by fusing the herpes simplex virus protein VP16—involved in recruitment of chromatin 
remodeling factors that increase chromatin accessibility—and its VP64 tetrameric form to zinc 
finger proteins [41, 42]. For instance, an early study demonstrated that zinc finger proteins 
targeted to 18 base-pair sequences of the 5′ untranslated region of the proto-oncogene erbB-2 
could upregulate transcription in an endogenous context [41]. Upregulation was also shown 
to occur even under control of an exogenous chemical inducer molecule [41]. Similarly, zinc 
finger fusions to the VP64 activation domain have been used to reactivate dormant genes. In 
one study, a dormant mammary serine protease inhibitor (maspin) tumor suppressor gene was 
reactivated by targeting the maspin promoter region, which is often epigenetically silenced in 
aggressive epithelial tumors [43]. Other transcriptional activator domains, such as the p65 
subunit of the NF-κB complex, have also been coupled to zinc finger proteins for targeted 
transcriptional activation [44].
The proof-of-concept studies using zinc fingers fused to transcriptional activation domains 
to modulate gene expression patterns served as blueprints for the subsequent use of acti-
vator domain fusions to TALEs and CRISPR–dCas9 systems. TALE activators targeted to 
promoter sites of the endogenous human VEGF-A, NTF3, and the microRNA miR-302/367 
cluster have been reported to induce increased target gene expression by fivefold or more 
[28]. Endogenous levels of gene expression of select human pluripotency factors have also 
been shown to increase by twofold to fivefold using TALE fusions to VP64 [45].
Furthermore, although single TALE fusions to transcriptional activators have demon-
strated the ability to upregulate gene expression, combinations of TALE-VP64 fusions 
targeting the promoter regions of genes implicated in inflammation, immunomodulation, 
and cancer pathways have established the occurrence of synergistic activation effects at 
target sites, which presents opportunities to develop tunable transcriptional networks [46]. 
Interestingly, it appears that different types of transcriptional activators induce varying 
levels of gene expression. In one study, the mean-fold activation induced with TALE-p65 
activators was lower than that with TALE-VP64 activators [28]. The combination of VP64 
and p65 activators exhibits synergistic effects on endogenous gene expression, which can 
provide a platform not only to design tools for targeted gene expression, but also to fine-
tune the fold activation induced by different combinations of activator domains fused to 
DNA-binding proteins [28].
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Recently, researchers have built upon work on zinc finger and TALE fusions to develop 
technologies for targeted gene expression utilizing the CRISPR–dCas9 system. RNA-guided 
transcriptional upregulation using CRISPR–dCas9-VP64 and CRISPR–dCas9-p65 fusions has 
been reported by several research teams in the last 5 years [47–50]. Introduction of individual 
sgRNAs for dCas9 targeting can induce transcriptional activity at desired loci, but the use 
of multiple sgRNAs to target a single locus can act synergistically to induce multifold gene 
expression [48–50]. The CRISPR–dCas9 system offers several advantages over zinc fingers 
and TALEs for targeted gene activation. Because CRISPR–dCas9 is an RNA-guided, DNA-
targeting system, it does not require complex protein engineering and could open additional 
research paths for spatiotemporal control of gene expression alongside complex chemical and 
optogenetic inducible systems. However, some studies have reported that dCas9-based acti-
vation tools induce weaker levels of transcription compared to TALE-based activators [50, 51].
In addition to the use of transcriptional activators for targeted gene expression, research teams 
have demonstrated the efficacy of using epigenetic effectors fused to DNA targeting proteins 
to manipulate epigenetic landscapes. In 2015, a study reported the use of CRISPR–dCas9, 
TALE, and zinc finger fusions to the p300 histone acetyltransferase (HAT) catalytic domain, 
which deposits H3K27 and other acetylation marks on histone tails, to trigger transactiva-
tion of genes [39]. Notably, the study showed that CRISPR–dCas9-p300 Core fusions led to 
more efficient and robust activation from proximal and distal enhancer regions compared to 
synthetic transcription factors engineered to carry activation domains that target promoters. 
Other epigenetic effectors that catalyze covalent modifications on DNA have also been fused 
to DNA-binding proteins to induce gene expression. For example, ten-eleven translocation 
(TET) demethylase enzymes that catalyze the sequential oxidation of 5-methyldeoxycytosine 
(m5dC) to form 5-hydroxymethylcytosine (hm5C), 5-formylcytosine (f5C), and 5-carboxylcyto-
sine (ca5C) have been used with zinc fingers [52–54], TALEs [55], and CRISPR–dCas9 [56, 57] 
to direct promoter-specific DNA demethylation and, thus, upregulate gene expression.
As mentioned earlier, CRISPR–dCas9 systems represent promising tools for the next genera-
tion of complex inducible systems. More recently, a novel system comprising CRISPR–dCas9 
fused to a tripartite activator featuring the constituent activation domains VP64, p65, and 
Rta (VPR) was shown to activate endogenous coding and noncoding regions while target-
ing several genes simultaneously [58]. Another platform built with CRISPR–dCas9 and a 
protein scaffold—namely, a repeating peptide array called the SUperNova tagging system 
(SunTag)—capable of recruiting multiple copies of an antibody fusion protein showed robust 
levels of endogenous gene activation at target sites [59]. Lastly, it has been demonstrated that 
CRISPR–Cas sgRNAs can be engineered to carry protein-binding cassettes, artificial aptam-
ers, and other ncRNAs directly into the sgRNA stem-loop structures, thereby creating modu-
lar CRISPR–dCas9 complexes that enable locus targeting, multiplexing, and highly inducible 
regulatory action to upregulate patterns of gene expression [60–62].
3.2. Transcriptional repression
Silencing endogenous gene expression at target loci has been achieved in similar ways to 
gene activation by fusing repressor domains or epigenetic effectors to DNA-binding proteins. 
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The domain most commonly used to trigger gene silencing is the Krüppel-associated box 
(KRAB). KRAB repression is mediated by the recruitment of complexes that elicit forma-
tion of heterochromatin via interactions between the KRAB-associated protein 1 (KAP1) 
corepressor and other factors that catalyze histone methylation and deacetylation [17, 63]. 
KRAB fusions to zinc finger proteins [41, 64], TALEs [65], and CRISPR–dCas9 [40, 47] have 
demonstrated robust inactivation from promoter as well as proximal and distal regulatory 
elements.
Although the KRAB repressor is the most common domain used for recruitment of hetero-
chromatin-forming factors, researchers have also reported efficient gene silencing with other 
repressor domains such as the mSin interaction domain (SID) [65] and Mxi1 [47]. One study 
comparing dCas9-KRAB and dCas9-Mxi1 showed that the Mxi1 fusion could induce more 
repression by nearly threefold levels [47]. A separate study found that TALE-SID repres-
sors could lead to 26% more transcriptional repression than its TALE-KRAB counterparts 
[65]. Moreover, concatenating four SID (SID4X) domains—much like combining VP16 units 
into VP64 activator proteins—and fusing them to DNA-binding proteins can induce greater 
repression than single SID domain fusions [66].
In contrast to transcriptional repressors, which aptly recruit heterochromatin-forming com-
plexes to desired loci, epigenetic effectors can directly catalyze specific modifications on 
histones and DNA that trigger targeted epigenetic repression. Several studies have thus far 
tested and confirmed robust repression efficiency rates of histone methyltransferases [17], 
histone demethylases [29, 67], and DNA methyltransferases [68–70] with zinc finger, TALE, 
and CRISPR–dCas9 proteins at target promoter and enhancer regions.
Notably, a study featuring a CRISPR–dCas9 fusion to the catalytic domain of DNMT3A, 
a de novo DNA methyltransferase, found that multiplexing with several sgRNAs exhibits 
synergistic effects on site-specific CpG methylation [70]. Thus, CRISPR–dCas9-DNMT3A 
multiplexing can lead to a greater increase of methylation levels at target regions. Despite 
the synergistic effects seen with DNMT3A repressor fusions, it appears that dCas9-
DNMT3A epigenetic editing of target CpG methylation sites is not wholly stable and does 
not persist beyond the loss of expression of the editing construct [70]. To overcome this 
type of transient epigenetic editing, a study recently reported a system for inheritable 
silencing of endogenous genes by transiently expressing combinations of DNA-binding 
proteins fused to transcriptional repressors, including KRAB and DNMT3 domains, to 
prompt long-term memory of repressive epigenetic states [71]. Lastly, the modular nature 
of sgRNAs has enabled the creation of scaffolding systems to achieve multiplexing and 
multimerization of epigenetic effectors, which will be useful to study endogenous and 
synthetic gene repression [62, 72].
3.3. Technological limitations
Epigenome editing directed by catalytically active or scaffolding epigenetic effectors fused 
to programmable DNA binding proteins has contributed important insights about the causal 
relationships between epigenetic states and gene regulation. However, despite the progress 
made in recent years to uncover the molecular basis of epigenetic processes, epigenome editing 
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remains a nascent field that must overcome many technological challenges related to editing 
efficiency, delivery, cytotoxicity, and specificity.
A major current limitation concerns the spatio-temporal specificity of epigenome editing, 
which may involve multiple factors including, but not limited to, non-specific deposition or 
removal of select epigenetic marks on target DNA loci or histones, mitigation of off-target 
DNA binding effects, and temporal expression of epigenetic effectors in different cell types 
and chromatin contexts [3]. For example, enzymes that catalyze the deposition of histone 
PTMs—e.g., p300’s HAT domain, which catalyzes acetylation of multiple residues on all four 
core histones—have various degrees of histone substrate specificity. Thus, the inherent pro-
miscuity of an enzyme may pose challenges to the study of direct functional roles for unique 
PTMs in specific contexts [3].
Similarly, the expression levels and times at which an epigenetic effector is present in a cell 
type can exert effects on the efficiency of DNA binding specificity. Following target site satu-
ration, off-target binding activity is likely to increase if the effector remains, or continues to be 
expressed, in the cell. This could partly explain the extensive global off-target effects reported 
with the use of dCas9–methyltransferase fusions in one study [73]. Given the lack of target site 
specificity previously reported for dCas9–sgRNA complexes [74], further research is needed 
to establish whether other dCas9–effector fusions exhibit similar off-target activities. The 
use of zinc finger and TALE fusions to epigenetic effectors offers an alternative to mitigate 
possible dCas9-related off-target effects. However, zinc finger and TALE epigenome editing 
biotechnologies are limited by the complex protein engineering required to mediate DNA 
recognition.
Progress in other areas associated with challenges in delivery, efficiency, and stability of 
epigenetic states has come at a rapid pace [75–77]. Chemical and optogenetic molecules 
have expanded the toolbox for reversible and inducible epigenome editing in endogenous 
contexts [3, 66, 78]. And emerging technologies for RNA editing [79] could soon provide 
new insights about the epigenetic roles of ncRNAs. As the field matures, epigenome editing 
will undoubtedly make significant contributions to the advancement of basic and applied 
research.
4. Conclusion
Recent technological breakthroughs in epigenome editing have expanded our understanding 
of the underlying mechanisms responsible for the regulation of chromatin structure and the 
spatiotemporal control of gene activation and repression. As detailed in this chapter, modern 
epigenome editing systems are revolutionizing the field of epigenetics. Programmable DNA-
binding proteins fused to catalytically active or scaffolding epigenetic effectors represent 
invaluable tools to uncover the functional significance of site-specific epigenetic mechanisms 
in a myriad of contexts including development, cell differentiation, and disease. Undoubtedly, 
progress in this emerging field will offer great contributions to translational medicine and 
biotechnology in the near future.
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Acronyms and abbreviations
PTM post-translational modification
ncRNA noncoding RNA
ZFN zinc finger nuclease
ATF artificial transcription factor
TALEN transcription activator-like effector nuclease
RVD repeat variable diresidue
CRISPR clustered, regularly interspaced, short palindromic repeats
Cas CRISPR-associated sequences
pre-RNA precursor CRISPR RNA
crRNA CRISPR RNA
tracrRNA trans-activating crRNA
sgRNA single-guide RNA
NHEJ nonhomologous end joining
HDR homology-directed repair
TFO triple helix-forming oligonucleotide
MASPIN mammary serine protease inhibitor
HAT histone acetyltransferase
TET ten-eleven translocation
m5dC 5-methyldeoxycytosine
hm5C 5-hydroxymethylcytosine
f5C 5-formylcytosine
ca5C 5-carboxylcytosine
VPR VP64, p65, and Rta
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SunTag SUperNova tagging
KRAB Krüppel-associated box
KAP1 KRAB-associated protein 1
SID mSin interaction domain
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